News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a valuation analysis for Genmab A/S (GMAB), noting its current valuation score of 9.22, ranking it 48th in the Biotechnology & Medical Research industry. The company's P/E ratio is 21.48, which is slightly below its recent high but significantly above its …
Sharemaestro market context Price above Trend Line 52 weeks +29.6%This article provides a technical analysis of Genmab A/S (GMAB), focusing on its support and resistance levels, various technical indicators, and moving averages. While the stock's price momentum score is low within its industry, its current trading range suggests suitability for range-bound swing trading. …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup positive 55.7%Genmab reported strong first-half results, with DARZALEX sales reaching $8.17 billion, already exceeding half of its $16 billion full-year target. If second-half sales remain consistent, the company is on track to surpass its full-year guidance with total projected sales of $16.59 billion, further boosted …
This article provides a comprehensive stock analysis of Genmab A/S (GMAB) highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and a forecasted upward trend, the technicals currently suggest a sideways trading …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup positive 55.7%Genmab A/S (FWB:GE9) generated 3.17 billion EUR in revenue last year, with its Antibody Therapeutics segment contributing the most at 3.29 billion EUR. The largest regional contribution came from Denmark, accounting for 2.94 billion EUR. The article provides a high-level overview of the company's …
Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab (GMAB) with a price target of $33.00. This follows a recent upgrade to Buy from Hold by TD Cowen. Genmab reported quarterly revenue of $899.32 million and a net profit of $53.2 million, …
Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …
(RTTNews) - Genmab A/S (GMAB) and AbbVie Inc. (ABBV) on Thursday announced that the Phase 3 EPCORE DLBCL-1 trial evaluating Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) failed to meet its U.S. primary endpoint of overall survival (OS). …
Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …
Genmab A/S stock is maintaining a steady trade as investors analyze the company's recent strong revenue growth from its antibody-driven oncology treatments and its positive profitability trends. The biotechnology company balances its established commercial products with significant investment in its pipeline of clinical-stage oncology …
Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup positive 55.7%TD Cowen has upgraded Genmab (GMAB) from Hold to Buy, significantly increasing its price target from $32.00 to $43.00. This upgrade signals a positive outlook on the biopharmaceutical company's growth and market position. GuruFocus assesses GMAB as 17.7% undervalued with a strong GF Score …
TD Cowen has upgraded Genmab (GMAB) stock from a "Hold" to a "Buy" rating. The firm also increased its price target for Genmab shares to $43 from $32. This upgrade reflects a more optimistic outlook on the biotechnology company's future performance.
TD Cowen upgraded Genmab A/S to Buy from Hold and raised its price target to $43.00 due to confidence in the company's drug pipeline, specifically Epkinly, Rina-S, and peto, which are expected to offset the Darzalex patent cliff. The firm believes the stock is …
Genmab's stock performance reflects its latest financial results and pipeline developments, with the company reporting increased revenue and operating profit for 2025. The company's cash generation and improved operating margin highlight its financial health, while its valuation remains heavily linked to its antibody pipeline …
Goldman Sachs has increased its price target for Genmab A/S to 2,350 Danish kroner from the previous 2,300, while maintaining a "buy" rating on the stock. This update reflects the firm's continued confidence in the biotechnology company specializing in cancer treatments and other therapeutic …
Genmab A/S announced that worldwide net trade sales of its drug DARZALEX (daratumumab), including the subcutaneous product DARZALEX FASPRO®, totaled USD 4,207 million in the second quarter of 2026. The sales were split with USD 2,435 million in the U.S. and USD 1,772 million …
Search by ticker symbol or company name and select a result to open its chart.